192 related articles for article (PubMed ID: 19308288)
1. Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration.
Walenkamp AM; Boer IG; Bestebroer J; Rozeveld D; Timmer-Bosscha H; Hemrika W; van Strijp JA; de Haas CJ
Neoplasia; 2009 Apr; 11(4):333-44. PubMed ID: 19308288
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
3. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
[TBL] [Abstract][Full Text] [Related]
5. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
6. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
7. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.
Panneerselvam J; Jin J; Shanker M; Lauderdale J; Bates J; Wang Q; Zhao YD; Archibald SJ; Hubin TJ; Ramesh R
PLoS One; 2015; 10(3):e0122439. PubMed ID: 25775124
[TBL] [Abstract][Full Text] [Related]
8. Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells.
Wang Y; Liang WC; Pan WL; Law WK; Hu JS; Ip DT; Waye MM; Ng TB; Wan DC
Phytomedicine; 2014 Sep; 21(11):1310-7. PubMed ID: 25172795
[TBL] [Abstract][Full Text] [Related]
9. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
10. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
Van Hout A; D'huys T; Oeyen M; Schols D; Van Loy T
PLoS One; 2017; 12(4):e0176057. PubMed ID: 28410420
[TBL] [Abstract][Full Text] [Related]
12. The good and bad faces of the CXCR4 chemokine receptor.
Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
[TBL] [Abstract][Full Text] [Related]
13. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
15. Expression of chemokine CXCL12 and its receptor CXCR4 in folliculostellate (FS) cells of the rat anterior pituitary gland: the CXCL12/CXCR4 axis induces interconnection of FS cells.
Horiguchi K; Ilmiawati C; Fujiwara K; Tsukada T; Kikuchi M; Yashiro T
Endocrinology; 2012 Apr; 153(4):1717-24. PubMed ID: 22355073
[TBL] [Abstract][Full Text] [Related]
16. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
17. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
18. Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-κB activation in breast and pancreatic tumor cells.
Chua AW; Hay HS; Rajendran P; Shanmugam MK; Li F; Bist P; Koay ES; Lim LH; Kumar AP; Sethi G
Biochem Pharmacol; 2010 Nov; 80(10):1553-62. PubMed ID: 20699088
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
[TBL] [Abstract][Full Text] [Related]
20. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
